Sandbox Reserved 1227
From Proteopedia
(Difference between revisions)
Line 4: | Line 4: | ||
== Function == | == Function == | ||
- | MDM2 is an E3 ubiquitin ligase that is specific to the p53 pathway. MDM2 is one of the main negatively regulatory proteins of the p53 pathway. | + | MDM2 is an E3 ubiquitin ligase that is specific to the p53 pathway. MDM2 is one of the main negatively regulatory proteins of the p53 pathway. Date involving MDM2 and the SNP285 polymorphism within its promotor region have been researched and is significantly linked to a decreased cancer risk<ref>Wang, P., Wang, M., Li, S., Ma, L., Xi, S., & He, J. (2016). Association of the MDM2 SNP285 Polymorphism with Cancer Susceptibility: A Meta-Analysis. Disease Markers, 20164585484.</ref>. |
== Relevance == | == Relevance == |
Revision as of 19:14, 29 March 2017
This Sandbox is Reserved from Jan 17 through June 31, 2017 for use in the course Biochemistry II taught by Jason Telford at the Maryville University, St. Louis, USA. This reservation includes Sandbox Reserved 1225 through Sandbox Reserved 1244. |
To get started:
More help: Help:Editing |
MDM2
|
References
- ↑ Wang, P., Wang, M., Li, S., Ma, L., Xi, S., & He, J. (2016). Association of the MDM2 SNP285 Polymorphism with Cancer Susceptibility: A Meta-Analysis. Disease Markers, 20164585484.
- ↑ Trino, S., De Luca, L., Laurenzana, I., Caivano, A., Del Vecchio, L., Martinelli, G., & Musto, P. (2016). P53-MDM2 Pathway: Evidences for A New Targeted Therapeutic Approach in B-Acute Lymphoblastic Leukemia. Frontiers in Pharmacology, 7, 491. http://doi.org/10.3389/fphar.2016.00491.
- ↑ Ciemny, M. P., Debinski, A., Paczkowska, M., Kolinski, A., Kurcinski, M., & Kmiecik, S. (2016). Protein-peptide molecular docking with large-scale conformational changes: the p53-MDM2 interaction. Scientific Reports, 6, 37532. http://doi.org/10.1038/srep37532.